Divi's Laboratories Limited (BOM:532488)
India · Delayed Price · Currency is INR 8,056.65
+216.15 (2.76%)
At close: Jul 31, 2026
Divi's Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 112,300 | 105,600 | 93,600 | 78,450 | 77,670 | 89,598 |
Other Revenue | - | - | - | - | - | 0.9 |
| 112,300 | 105,600 | 93,600 | 78,450 | 77,670 | 89,599 | |
Revenue Growth | 16.35% | 12.82% | 19.31% | 1.00% | -13.31% | 28.56% |
Cost of Revenue | 43,530 | 43,230 | 39,350 | 33,590 | 32,740 | 31,662 |
Gross Profit | 68,770 | 62,370 | 54,250 | 44,860 | 44,930 | 57,938 |
Selling, General & Admin | 15,280 | 14,600 | 12,580 | 11,060 | 9,870 | 9,571 |
Other Operating Expenses | 13,750 | 13,360 | 11,950 | 11,710 | 11,370 | 9,526 |
Operating Expenses | 33,870 | 32,590 | 28,550 | 26,550 | 24,670 | 22,212 |
Operating Income | 34,900 | 29,780 | 25,700 | 18,310 | 20,260 | 35,726 |
Interest Expense | -260 | -230 | -20 | -30 | - | -3.7 |
Interest & Investment Income | 2,840 | 2,840 | 2,950 | 3,010 | 2,050 | 689.6 |
Currency Exchange Gain (Loss) | 1,650 | 2,110 | 480 | 300 | 1,300 | 405.8 |
Other Non Operating Income (Expenses) | -80 | 80 | 40 | 30 | 40 | 38.1 |
EBT Excluding Unusual Items | 39,050 | 34,580 | 29,150 | 21,620 | 23,650 | 36,856 |
Gain (Loss) on Sale of Investments | 40 | 40 | 50 | 50 | 50 | - |
Gain (Loss) on Sale of Assets | - | - | -40 | -40 | -10 | -20.5 |
Other Unusual Items | -740 | -740 | - | - | - | - |
Pretax Income | 38,350 | 33,880 | 29,160 | 21,630 | 23,690 | 36,835 |
Income Tax Expense | 9,100 | 8,200 | 7,250 | 5,630 | 5,450 | 7,231 |
Net Income | 29,250 | 25,680 | 21,910 | 16,000 | 18,240 | 29,605 |
Net Income to Common | 29,250 | 25,680 | 21,910 | 16,000 | 18,240 | 29,605 |
Net Income Growth | 26.84% | 17.21% | 36.94% | -12.28% | -38.39% | 49.19% |
Shares Outstanding (Basic) | 265 | 265 | 265 | 265 | 265 | 265 |
Shares Outstanding (Diluted) | 265 | 265 | 265 | 265 | 265 | 265 |
Shares Change | -0.08% | - | - | - | - | - |
EPS (Basic) | 110.21 | 96.73 | 82.53 | 60.27 | 68.71 | 111.52 |
EPS (Diluted) | 110.21 | 96.73 | 82.53 | 60.27 | 68.69 | 111.52 |
EPS Growth | 26.95% | 17.21% | 36.93% | -12.26% | -38.41% | 49.19% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 2,180 | 2,150 | 2,580 | 19,860 | 11,986 |
Free Cash Flow Per Share | - | 8.21 | 8.10 | 9.72 | 74.81 | 45.15 |
Dividend Per Share | - | 30.000 | 30.000 | 30.000 | 30.000 | 30.000 |
Dividend Growth | - | 0% | 0% | 0% | 0% | 50.00% |
Gross Margin | 61.24% | 59.06% | 57.96% | 57.18% | 57.85% | 64.66% |
Operating Margin | 31.08% | 28.20% | 27.46% | 23.34% | 26.09% | 39.87% |
Profit Margin | 26.05% | 24.32% | 23.41% | 20.39% | 23.48% | 33.04% |
Free Cash Flow Margin | - | 2.06% | 2.30% | 3.29% | 25.57% | 13.38% |
EBITDA | 39,655 | 34,380 | 29,680 | 22,050 | 23,640 | 38,801 |
EBITDA Margin | 35.31% | 32.56% | 31.71% | 28.11% | 30.44% | 43.30% |
D&A For EBITDA | 4,755 | 4,600 | 3,980 | 3,740 | 3,380 | 3,075 |
EBIT | 34,900 | 29,780 | 25,700 | 18,310 | 20,260 | 35,726 |
EBIT Margin | 31.08% | 28.20% | 27.46% | 23.34% | 26.09% | 39.87% |
Effective Tax Rate | 23.73% | 24.20% | 24.86% | 26.03% | 23.00% | 19.63% |
Revenue as Reported | 116,820 | 110,670 | 97,120 | 81,840 | 81,120 | 90,737 |
Advertising Expenses | - | - | - | - | - | 1.6 |